What do systematic reviews say?

Summary of findings ‐ monotherapy: lumacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 115 participants
  Very low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 26 participants
  Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor showed no clear difference in overall adverse events compared with crizotinib (moderate certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  RR 1 [0.98, 1.01]
  5 studies · 1263 participants
  Moderate

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with crizotinib (low certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  RR 0.85 [0.49, 1.47]
  5 studies · 1263 participants
  Low

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor probably leads to lower overall survival compared with crizotinib (moderate certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.71 [0.56, 0.9]
  5 studies · 1263 participants
  Moderate

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor probably leads to higher overall response rate compared with crizotinib (moderate certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  RR 1.18 [1.1, 1.25]
  5 studies · 1229 participants
  Moderate

Next‐generation ALK inhibitor vs crizotinib

It is very uncertain whether next‐generation ALK inhibitor changes health‐related quality of life: time to deterioration in composite… compared with crizotinib (very low certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 1.1 [0.72, 1.68]
  1 study · 303 participants
  Very low

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor leads to lower progression‐free survival: overall population compared with crizotinib (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.39 [0.32, 0.46]
  5 studies · 1263 participants
  High

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with crizotinib (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.25 [0.19, 0.34]
  5 studies · 406 participants
  High

Summary of findings table ‐ Cognitive rehabilitation vs inactive control

• Cognitive rehabilitation for people with mild to moderate dementia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 673 participants
  Low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 62 participants
  Moderate

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor vs placebo

The review found no eligible studies for this question.

• Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found